Cadence Biomedical is an early-stage medical device company that focuses on mobility impairments.
Cadence Biomedical, headquartered in Seattle, WA, is an early-stage medical device company that is committed to helping the 2.3 million Americans who suffer severe mobility impairments to gain a more mobile and independent life.Cadence Biomedical's primary commercial product, Kickstart, is a neurorehabilitation device designed to accelerate recovery to walking in stroke, multiple sclerosis, spinal cord injury patients, and individuals with other progressive neurological conditions. Kickstart is available for use in physical therapy during the initial recovery process and as a prescribed device for post-discharge use in the community and home settings.The company is currently developing a new class of device, a kinetic orthosis, based on a novel exotendon technology invented at the Cleveland Clinic by world-renowned researcher Dr. A.J. van den Bogert. Cadence closed its first round of funding in August 2010 (as Empowering Engineering Technologies, Corp.) and signed a perpetual, worldwide exclusive license agreement with the Cleveland Clinic to develop and market the technology. Market release of the kinetic orthosis is expected in early 2012.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Jun 25, 2015 | Series B | $1.20M | 1 | — | — | Detail |
Apr 26, 2012 | Series A | $1.10M | 1 | — | — | Detail |
Jan 20, 2012 | Series Unknown | $750K | 1 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
BioPacific Ventures | — | Series B |
Keiretsu Forum | — | Series A |